Seoul, South Korea

Kyoungsook Park

USPTO Granted Patents = 4 

Average Co-Inventor Count = 2.4

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2011-2020

Loading Chart...
4 patents (USPTO):Explore Patents

Title: Kyoungsook Park: Innovator in Muscular Atrophy and Cancer Research

Introduction

Kyoungsook Park is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the fields of muscular atrophy and cancer research. With a total of 4 patents, his work focuses on innovative solutions for treating various health conditions.

Latest Patents

Kyoungsook Park's latest patents include a muscular atrophy-inducing agent that utilizes a hypometabolism-inducing substance known as T1AM. This invention aims to treat muscular hypertrophy and provides a method for preparing a muscular atrophy study model. The study model can be used for screening drugs that prevent or treat muscular atrophy. Another notable patent involves an agent that inhibits angiogenesis and metastasis by targeting the mTOR signaling pathway. This invention highlights the novel function of the Msx1 protein in suppressing tumor angiogenesis, which is crucial for the growth and spread of solid tumors.

Career Highlights

Throughout his career, Kyoungsook Park has worked at esteemed institutions such as Sungkyunkwan University and Yonsei University. His research has led to groundbreaking advancements in understanding muscular atrophy and cancer treatment.

Collaborations

Kyoungsook Park has collaborated with notable colleagues, including Je-Ho Lee and Inho Choi. Their combined efforts have contributed to the development of innovative research in their respective fields.

Conclusion

Kyoungsook Park's contributions to science and medicine through his patents and research are invaluable. His work continues to pave the way for advancements in treating muscular atrophy and cancer.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…